1. No category

P087
Average rates of chromogranin A in patients
with various prostate diseases
Apolikhin OI, Sivkov AV, Efremov GD, Rabinovitch EZ, Keshishev NG, Kovchenko GA,
Prokhorov SA, Sokov DG, Nikonova LM.
State Federal Institute of Urology of the Health Ministry of Russia, Moscow
Introduction
Diagnosis
It is considered that neuroendocrine cells
(NEC) are always present in prostate cancer
(PCa) in various amounts. NEC markers are:
chromogranin
A
(ChA),
serotonin,
secretogranin, thyroid stimulating hormone,
calcitonin, katacalcin, parathyroid hormone
etc. Most sensitive and clinically proven
serum marker in the identification of
neuroendocrine differentiation (NED) of PCa
is serum ChA (sChA). However, in the
literature we have not found data on the level
of sChA in various prostate diseases.
Control group
27
1,28±0,11
BPH
20
0,940,16
ChP
Patients
number
21
Average rates of sChA (nmol/l)
p>0,05
1,240,13
p>0,05
1,26 0,09
BPH + LPIN
49
BPH + HPIN
31
1,77 0,15
LPC
78
1,78 0,14
LAPC
20
2,71 0,53
CRPC
46
3,51 0,42
Total number
292
p>0,05
p<0,05
p<0,05
Fig.1. Average rates of sChA in patients with various
prostate diseases
Number of patients with sChA level more than
The aim
3 nmol/l was higher in patients with CRPC
To determine the average values of the sChA comparing to patients with LAPC and LPC:
for various prostate diseases.
34%, 25% and 11,5% correspondingly
(р<0,05). SChA level in patients with CRPC
Methods
was statistically higher than in patients with
The study included 292 patients with prostate
LAPC and LPC: 3,51, 2,71 and 1,78 nmol/l
diseases: benign prostatic hyperplasia (BPH),
correspondingly (р<0,05) (Fig.2).
chronic prostatitis (ChP), BPH and low-grade
prostatic intraepithelial neoplasia, (BPH +
CRPC
34
LAPC
25
LPIN), BPH and high-grade prostatic
11,5
LPC
intraepithelial neoplasia (BPH + HPIN),
BPH + HPIN
10
BPH + LPIN
4
localized prostate cancer (LPC), locally
ChP
4,7
advanced prostate cancer (LAPC), castrationBPH
5
resistant prostate cancer (CRPC), control Control group 0
0
5
10
15
20
25
30
35
40
group. SChA was determined in all these
patients by ELISA on automated analyzer
Fig.2. Number of patients with sChA level more than
«Gemini» (ELISA kit EuroDiagnostica). The
3 nmol/l (%)
reference values of sChA were up to 3 nmol/L.
Results
Conclusion
Comparative analysis of the 4 groups of
patients (BPH, ChP, BPH + LPIN, BPH +
HPIN) has not revealed any statistical
difference (р>0,05), however average rates of
sChA statistically differed in patients with LPC
and
LAPC:
1,78
and
2,71
nmol/l
correspondingly (р<0,05) (Fig.1).
SChA is a valuable marker for prostate cancer.
Significant correlation of sChA is observed in
prostate diseases, particularly in PCa stages.
More than one third of patients with CRPC and
a quarter of patients with LAPC have signs of
NED. That is important for the development of
new treatment methods.
There is no financial support or incentive for this publication
www.uro.ru